Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Liraglutide
CAS: 204656-20-2
GLP-1 diario estudiado para la regulación constante del apetito
Liraglutide es un péptido de investigación en la categoría de GLP-1 / control de peso. Liraglutide es un agonista del receptor GLP-1 con 97% de homología de secuencia con el GLP-1 humano nativo. MiPeptidos ofrece Liraglutide en 3 tamaños con 99.7% de pureza verificada y documentación analítica completa.
- Control diario del hambre
- Pérdida de grasa constante y sostenible
- Beneficios para la salud cardiovascular
- Perfil de seguridad bien estudiado
Los estudios sugieren que la reducción del apetito comienza dentro de los primeros días de iniciar Liraglutide, ya que se dosifica diariamente en lugar de semanalmente. Entre las semanas 2-4, los estudios reportan sentirse lleno más rápido en las comidas y reducción de los antojos entre comidas. La pérdida de peso es gradual pero constante, alrededor de 0.5 kg por semana. Debido a su dosificación diaria, algunos investigadores prefieren el control del apetito más constante en comparación con las inyecciones semanales donde el hambre puede regresar hacia el final de la semana.
$10.90/vial · Everything you need to start
Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
The Proven GLP-1 Pioneer.
16-week protocol backed by the SCALE program and 10+ years of real-world GLP-1 safety data
Liraglutide is a GLP-1 receptor agonist with 97% structural homology to native human GLP-1. Approved as Victoza (1.8mg daily, diabetes) and Saxenda (3.0mg daily, obesity), it was the first GLP-1 RA approved specifically for chronic weight management. The SCALE clinical program demonstrated consistent 8% mean weight loss, and importantly, liraglutide has the longest real-world safety track record of any GLP-1 agonist, with FDA approval since 2010.
Resultados Publicados
Revisado por ParesResultados cuantificables de investigación clínica publicada.
Lo que Dicen los Expertos
4 MédicosProfesionales e investigadores líderes que han estudiado y prescrito este péptido.
Dr. Xavier Pi-Sunyer
Professor of Medicine, Columbia University Irving Medical Center
Lead investigator of SCALE Obesity and Prediabetes trial. Director of the New York Obesity Research Center. Over 40 years in obesity research. MD, MPH.
Liraglutide 3.0mg produced clinically meaningful weight loss that was maintained over 56 weeks, with significant improvements in cardiometabolic risk factors.
Dose escalation from 0.6mg to 3.0mg over 4-5 weeks is critical for GI tolerability. If 3.0mg is not tolerated, 2.4mg daily is an acceptable maintenance dose.
Fuente: SCALE Obesity and Prediabetes (NEJM, 2015, PMID: 26132941)
Dr. John Buse
Director, Diabetes Center, University of North Carolina School of Medicine
Past President of the American Diabetes Association. Professor of Medicine and Chief of Endocrinology at UNC. Leading voice in incretin therapeutics.
Liraglutide established the proof of concept that GLP-1 receptor agonists could be effective anti-obesity agents. It paved the way for everything that followed.
Liraglutide's daily dosing provides more stable drug levels than weekly agents. Useful for patients who experience 'end-of-week hunger' on semaglutide or tirzepatide.
Fuente: ADA Scientific Sessions presentations; Diabetes Care reviews
Dr. Stephen Bloom
Professor of Medicine, Imperial College London
Head of the Division of Diabetes, Endocrinology and Metabolism at Imperial. Pioneer in gut hormone research and appetite regulation. FRS, FMedSci.
The GLP-1 system is fundamental to appetite regulation. Liraglutide's success validated decades of gut hormone research and opened the door to an entirely new class of obesity treatments.
Daily dosing achieves steady-state GLP-1R activation with less peak-trough variability than weekly formulations. May suit patients sensitive to the bolus effect of weekly injections.
Fuente: Imperial College research publications; Gut Hormones review series
Dr. Donna Ryan
Professor Emerita, Pennington Biomedical Research Center
Past President of The Obesity Society. Co-chair of the AMA Obesity Advisory Group. Over 30 years leading obesity clinical trials.
Liraglutide 3.0mg demonstrated that pharmacotherapy, when combined with lifestyle modification, produces durable weight loss. The 10-year safety record gives clinicians confidence.
The SCALE trials showed best results when combined with a 500 kcal/day deficit and 150 minutes/week of exercise. Liraglutide alone without lifestyle changes produces modest results.
Fuente: SCALE Maintenance trial (Int J Obesity, 2013); Obesity Society guidelines
Protocolo de Dosificación
3 FasesRégimen de dosificación paso a paso compilado de profesionales líderes e investigación clínica.
Starting dose for GI tolerability. This is not a therapeutic dose. Inject at approximately the same time each day. Can be taken with or without food.
Increase by 0.6mg each week. If GI intolerance occurs at any level, remain at current dose for an additional week before escalating. The 1.8mg dose is the Victoza (diabetes) maintenance dose.
Target maintenance dose for weight management (Saxenda dose). SCALE demonstrated sustained efficacy at 56 weeks. If 3.0mg not tolerated, 2.4mg is acceptable. Discontinue if <4% weight loss at 16 weeks.
Research-grade lyophilized liraglutide: reconstitute 5mg vial with 1mL bacteriostatic water = 5mg/mL. For 0.6mg dose = 0.12mL (12 units). For 3.0mg dose = 0.6mL (60 units). Daily dosing means one 5mg vial lasts ~1.7 days at maintenance dose.
Liraglutide is designed for continuous daily use — not cycled. The SCALE program demonstrated sustained efficacy at 56 weeks. Weight regain occurs upon discontinuation. If stopping, taper by 0.6mg per week to minimize rebound.
Lyophilized: store at -20°C. Reconstituted: refrigerate at 2-8°C, use within 30 days. Branded pens (Victoza/Saxenda): refrigerate unused; once in use, room temp or 2-8°C for up to 30 days.
Subcutaneous injection once daily at approximately the same time each day. Rotate injection sites. Can be administered at any time, with or without meals. The ~13-hour half-life supports once-daily dosing with relatively stable plasma levels.
Cronología de Recuperación
Basado en observaciones de investigación publicada. Los resultados individuales varían. Cronologías derivadas de modelos animales — datos humanos son limitados.
GI Adaptation & Initial GLP-1 Activation
- GLP-1 receptor activation initiates — glucose-dependent insulin secretion enhanced
- Mild appetite suppression as hypothalamic satiety pathways engage
- Nausea most common in first 1-2 weeks (~40% of patients)
- Gastric emptying begins to slow, contributing to early satiety
- Typical weight loss: 0.5-1.5% of body weight
Base de investigación: SCALE Obesity and Prediabetes (Pi-Sunyer et al., 2015, NEJM, PMID: 26132941)
Dose Escalation to Therapeutic Range
- Progressive escalation from 1.8mg to 3.0mg over weeks 3-5
- Significant appetite reduction at 2.4-3.0mg daily
- GI side effects typically stabilize by week 6-8
- Fasting glucose and postprandial glucose excursions improving
- Typical weight loss: 3-5% of body weight
Base de investigación: SCALE program dosing guidelines; Saxenda prescribing information
Active Weight Loss Phase
- Steady weight loss of 0.5-1.0 kg per week at maintenance dose
- Cardiometabolic markers improving: blood pressure, lipids, CRP
- HbA1c reduction of 0.4-1.6% in those with prediabetes or T2D
- 63% of patients achieve ≥5% weight loss by week 16
- If <4% loss at week 16, consider dose adjustment or alternative agent
Base de investigación: SCALE trials (PMID: 26132941); Saxenda label — 16-week assessment point
Sustained Maintenance & Long-Term Benefits
- Mean 8.0% weight loss maintained at 56 weeks (SCALE)
- 63.2% of patients maintained ≥5% weight loss
- 33.1% lost ≥10% of body weight at 56 weeks
- Prediabetes-to-diabetes conversion reduced by 80% over 3 years
- LEADER trial: 13% reduction in MACE events (HR 0.87) in T2D patients
Base de investigación: SCALE Obesity (PMID: 26132941); LEADER (Marso et al., 2016, NEJM, PMID: 27295427)
Mecanismo de Acción
3 vías biológicas distintas a través de las cuales opera este péptido.
GLP-1 Receptor Agonism (97% Homology)
Liraglutide shares 97% amino acid homology with native GLP-1, providing physiological receptor activation with enhanced half-life through C16 fatty acid albumin binding.
- 97% sequence identity to endogenous GLP-1 — most physiological of GLP-1 RAs
- C16 palmitoyl fatty acid chain enables albumin binding and ~13-hour half-life
- Activates GLP-1R for glucose-dependent insulin secretion (minimal hypo risk)
- Daily dosing provides steady-state levels with less peak-trough variation than weekly agents
Victoza/Saxenda prescribing information; Knudsen et al. (2000) J Med Chem
Hypothalamic Appetite Regulation
Crosses the blood-brain barrier to activate GLP-1 receptors in the hypothalamus, upregulating POMC/CART satiety pathways and downregulating NPY/AgRP hunger drive.
- Activates arcuate nucleus POMC neurons for satiety signaling
- Suppresses NPY/AgRP orexigenic neurons to reduce hunger
- Modulates mesolimbic reward circuits to reduce hedonic eating
- Steady daily dosing provides consistent appetite suppression vs weekly bolus
Secher et al. (2014) J Clin Invest (PMID: 24401271)
Cardiovascular Protection
Reduces major adverse cardiovascular events through anti-inflammatory, anti-atherosclerotic, and metabolic mechanisms that appear partially independent of weight loss.
- LEADER: 13% MACE reduction (HR 0.87) over 3.8 years in T2D patients
- Reduces systemic inflammation (CRP), blood pressure, and atherogenic lipids
- Direct vascular effects: reduced atherosclerotic plaque progression in animal models
- First GLP-1 RA to demonstrate cardiovascular benefit in a dedicated CVOT
LEADER trial (PMID: 27295427); Marso et al. (2016) NEJM
Investigación Publicada
5 estudios revisados por pares de PubMed. Haz clic en cualquier PMID para ver el estudio completo.
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes)
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. — New England Journal of Medicine (2015)
Hallazgo Clave: Liraglutide 3.0mg produced 8.0% mean weight loss vs 2.6% placebo at 56 weeks (n=3,731). 63.2% achieved ≥5% weight loss. Prediabetes prevalence reduced significantly.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER)
Marso SP, Daniels GH, Tanaka K, Poulter N, Emerson SS, et al. — New England Journal of Medicine (2016)
Hallazgo Clave: LEADER: Liraglutide reduced MACE by 13% (HR 0.87, 95% CI 0.78-0.97) in 9,340 T2D patients over 3.8 years. First GLP-1 RA to demonstrate CV safety and benefit.
Effect of Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8)
Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, et al. — JAMA (2022)
Hallazgo Clave: Head-to-head: liraglutide 3.0mg daily achieved 6.4% weight loss vs semaglutide's 15.8% — establishing liraglutide as less potent but still effective. Some patients tolerate liraglutide better.
Three years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in prediabetes (SCALE Prediabetes 3-Year)
le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, et al. — The Lancet (2017)
Hallazgo Clave: 3-year SCALE data: liraglutide reduced progression from prediabetes to T2D by 80% compared with placebo. Weight loss was maintained with continued treatment.
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN)
Armstrong MJ, Gaunt P, Aithal GP, Barber D, et al. — The Lancet (2016)
Hallazgo Clave: LEAN trial: Liraglutide 1.8mg daily achieved NASH resolution in 39% vs 9% placebo at 48 weeks. First randomized trial demonstrating GLP-1 RA efficacy in NASH.
Potencia tu Protocolo de Investigación
4 SinergiasLa investigación sugiere combinar Liraglutide con estos péptidos para mecanismos complementarios.
Daily liraglutide dosing means continuous GI exposure — BPC-157 protects the gastric mucosa from ongoing GLP-1-mediated GI stress.
Particularly relevant for liraglutide given its daily dosing creates more constant GI exposure than weekly agents. May reduce the ~13% nausea-driven discontinuation rate.
AOD-9604 may enhance direct fat metabolism, complementing liraglutide's appetite-mediated weight loss for patients seeking additional fat-loss support.
May boost fat-specific weight loss beyond liraglutide's ~8% mean. Particularly for patients who plateau on liraglutide alone.
Ipamorelin's targeted GH secretion helps preserve lean mass during liraglutide-induced weight loss without the side effects of broader GH secretagogues.
Ipamorelin is one of the cleanest GH secretagogues with minimal cortisol or prolactin effects, making it well-suited as an adjunct to daily GLP-1 therapy.
5-Amino-1MQ inhibits NNMT to boost NAD+ and cellular energy metabolism, complementing liraglutide's central appetite suppression with peripheral metabolic enhancement.
Addresses weight loss from two different angles: central satiety (liraglutide) and peripheral fat cell metabolism (5-Amino-1MQ).
Especificaciones
Cómo Funciona Liraglutide
Liraglutide is a GLP-1 receptor agonist with 97% sequence homology to native human GLP-1. The palmitoyl fatty acid modification enables non-covalent albumin binding, which delays renal clearance and DPP-IV degradation. It stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and activates hypothalamic satiety centers to reduce food intake.
Aplicaciones de Investigación
Precios
| Tamaño | Por Vial | Paquete de 10 | Ahorro |
|---|---|---|---|
5mg | $90.00 | $765.00 | — |
10mgOferta | $74.95$120.00 | $637.07 | 38% descuento |
30mgMejor Valor | $320.00 | $2720.00 | — |
Precios de paquete de 10 mostrados. Descuentos por volumen para 50+ viales — contáctenos.
Certificado de Análisis
Este COA es una muestra representativa. Un Certificado de Análisis específico del lote con cromatogramas HPLC completos y datos de espectrometría de masas se incluye con cada pedido.
Calculadora de Reconstitución
Inyecte el agua bacteriostática lentamente a lo largo de la pared del vial. Agite suavemente hasta disolver — nunca sacuda. Almacene la solución reconstituida a 2-8°C y use dentro de 30 días.
Reseñas de Clientes
Preguntas Frecuentes
Seguridad y Advertencias
Not FDA-approved in research peptide form
Only branded Victoza (1.8mg for T2D) and Saxenda (3.0mg for obesity) are FDA-approved. Research-grade liraglutide peptide is not approved for human use.
Thyroid C-cell tumors (Boxed Warning)
Liraglutide causes thyroid C-cell tumors in rodents at clinically relevant exposures. CONTRAINDICATED in patients with personal or family history of MTC or MEN 2.
Pancreatitis risk
Acute pancreatitis has been reported. Discontinue immediately if persistent severe abdominal pain occurs. Higher risk with history of pancreatitis or gallstones.
Solo para Fines de Investigación y Educación. No es consejo médico. No para consumo humano. Consulte a un médico autorizado antes de tomar cualquier decisión relacionada con la salud.
Péptidos Relacionados
Up to 50% OffSemaglutide
Estudiado clínicamente para una reducción de peso constante — una vez por semana
Up to 60% OffTirzepatide
El agonista dual más estudiado para la reducción de peso
Up to 42% OffRetatrutide
Agonista de triple receptor estudiado para una actividad metabólica mejorada
Up to 15% OffCagrilintide
Estudiado para vías de saciedad mediadas por amilina más allá del GLP-1